167 related articles for article (PubMed ID: 38262999)
1. Preventive treatment patterns in the adult migraine population: an observational UK study over 7 years.
Kernick D; Kondori N; Pain A; Mount J; Appel C; Ranopa M; Gulati T
BMC Prim Care; 2024 Jan; 25(1):34. PubMed ID: 38262999
[TBL] [Abstract][Full Text] [Related]
2. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes.
Foster SA; Hoyt M; Ye W; Mason O; Ford JH
Curr Med Res Opin; 2022 May; 38(5):653-660. PubMed ID: 34761723
[TBL] [Abstract][Full Text] [Related]
3. The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: A retrospective, observational analysis.
Moskatel LS; Graber-Naidich A; He Z; Zhang N
Headache; 2024 Feb; 64(2):188-194. PubMed ID: 37882379
[TBL] [Abstract][Full Text] [Related]
4. Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs other preventive migraine treatments in the United States.
Varnado OJ; Manjelievskaia J; Ye W; Perry A; Schuh K; Wenzel R
J Manag Care Spec Pharm; 2022 Aug; 28(8):818-829. PubMed ID: 35876297
[No Abstract] [Full Text] [Related]
5. Patient characteristics and treatment utilization among patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibody and novel acute medication.
Varnado OJ; Hoyt M; Ye W; Nicholson R
Curr Med Res Opin; 2022 Aug; 38(8):1451-1457. PubMed ID: 35762152
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway.
Zhou Z; Urman R; Gill K; Park AS; Vuvu F; Patel LB; Lu J; Wade RL; Frerichs L; Bensink ME
J Headache Pain; 2023 Nov; 24(1):153. PubMed ID: 37946113
[TBL] [Abstract][Full Text] [Related]
7. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
[TBL] [Abstract][Full Text] [Related]
9. Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study.
Charleston L; Talon B; Sullivan C; Anderson C; Kymes S; Regnier SA; Soni-Brahmbhatt S; Nahas SJ
J Headache Pain; 2023 Aug; 24(1):101. PubMed ID: 37532991
[TBL] [Abstract][Full Text] [Related]
10. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.
Ferrari MD; Diener HC; Ning X; Galic M; Cohen JM; Yang R; Mueller M; Ahn AH; Schwartz YC; Grozinski-Wolff M; Janka L; Ashina M
Lancet; 2019 Sep; 394(10203):1030-1040. PubMed ID: 31427046
[TBL] [Abstract][Full Text] [Related]
11. Novel Medications for the Treatment of Migraine.
Ceriani CEJ; Wilhour DA; Silberstein SD
Headache; 2019 Oct; 59(9):1597-1608. PubMed ID: 31559638
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan.
Suzuki K; Suzuki S; Shiina T; Tatsumoto M; Fujita H; Haruyama Y; Hirata K
Cephalalgia; 2023 May; 43(5):3331024231177649. PubMed ID: 37231663
[TBL] [Abstract][Full Text] [Related]
13. CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications.
Dodick DW
Cephalalgia; 2019 Mar; 39(3):445-458. PubMed ID: 30661365
[TBL] [Abstract][Full Text] [Related]
14. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis.
Hong P; Wu X; Liu Y
Clin Neurol Neurosurg; 2017 Mar; 154():74-78. PubMed ID: 28129635
[TBL] [Abstract][Full Text] [Related]
15. Basic Considerations for the Use of Monoclonal Antibodies in Migraine.
Levin M; Silberstein SD; Gilbert R; Lucas S; Munsie L; Garrelts A; Kennedy K; Everman N; Pearlman E
Headache; 2018 Nov; 58(10):1689-1696. PubMed ID: 30426478
[TBL] [Abstract][Full Text] [Related]
16. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
[TBL] [Abstract][Full Text] [Related]
17. Characteristics associated with response to subcutaneously administered anti-CGRP monoclonal antibody medications in a real-world community cohort of persons living with migraine: A retrospective clinical and genetic study.
Chase BA; Semenov I; Rubin S; Meyers S; Mark A; Makhlouf T; Chirayil TT; Maraganore D; Wei J; Zheng SL; Xu J; Epshteyn A; Pham A; Frigerio R; Markopoulou K
Headache; 2024 Jan; 64(1):68-92. PubMed ID: 38071464
[TBL] [Abstract][Full Text] [Related]
18. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?
Nagaraj K; Vandenbussche N; Goadsby PJ
Neurol India; 2021; 69(Supplement):S59-S66. PubMed ID: 34003149
[TBL] [Abstract][Full Text] [Related]
19. Observational Analysis of the Costs Associated with Acute Treatment of Breakthrough Migraine Attacks in Medicaid Patients Using Preventive Therapies.
Harris L; O'Connell T; Woolley JJ; L'Italien G; Martin T; Coric V; Moren JA
Adv Ther; 2023 Mar; 40(3):1141-1152. PubMed ID: 36648736
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
Tepper SJ; Fang J; Zhou L; Shen Y; Vo P; Abdrabboh A; Glassberg MB; Ferraris M
J Manag Care Spec Pharm; 2021 Sep; 27(9):1157-1170. PubMed ID: 33998825
[No Abstract] [Full Text] [Related]
[Next] [New Search]
